Editas Medicine Inc (EDIT) concluded trading on Thursday at a closing price of $1.89, with 3.41 million shares of worth about $6.45 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -65.57% during that period and on December 12, 2024 the price saw a loss of about -5.03%. Currently the company’s common shares owned by public are about 82.54M shares, out of which, 81.78M shares are available for trading.
Stock saw a price change of -1.05% in past 5 days and over the past one month there was a price change of -38.44%. Year-to-date (YTD), EDIT shares are showing a performance of -81.34% which decreased to -80.79% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.89 but also hit the highest price of $11.58 during that period. The average intraday trading volume for Editas Medicine Inc shares is 2.25 million. The stock is currently trading -16.19% below its 20-day simple moving average (SMA20), while that difference is down -32.87% for SMA50 and it goes to -60.57% lower than SMA200.
Editas Medicine Inc (NASDAQ: EDIT) currently have 82.54M outstanding shares and institutions hold larger chunk of about 67.87% of that.
The stock has a current market capitalization of $156.02M and its 3Y-monthly beta is at 1.87. It has posted earnings per share of -$2.56 in the same period. It has Quick Ratio of 3.75 while making debt-to-equity ratio of 0.22. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EDIT, volatility over the week remained 9.85% while standing at 7.66% over the month.
Stock’s fiscal year EPS is expected to drop by -30.46% while it is estimated to increase by 14.48% in next year. EPS is likely to shrink at an annualized rate of 1.70% for next 5-years, compared to annual growth of 2.88% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on December 11, 2024 offering an Equal weight rating for the stock and assigned a target price range of between $7 and $4 to it. Coverage by BofA Securities stated Editas Medicine Inc (EDIT) stock as an Underperform in their note to investors on November 25, 2024, suggesting a price target of $1 for the stock. Stock get a Buy rating from BofA Securities on August 08, 2024.
